Anzeige
Erschienen in:
27.03.2017 | case report
Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017
Einloggen, um Zugang zu erhaltenSummary
The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.